Last reviewed · How we verify
NCT03494530: LASER
Lixiana Acute Stroke Evaluation Registry
Phase 4 trial testing Edoxaban 60 MG in Ischemic Stroke in 70 participants. Completed in 1 December 2021.
1 December 2021
Quick facts
| Lead sponsor | University of Alberta |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 70 |
| Start date | 1 June 2018 |
| Primary completion | 1 December 2021 |
| Estimated completion | 1 December 2021 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Edoxaban 60 MG — full drug profile →
- Edoxaban 30 mg — full drug profile →
Conditions studied
- Ischemic Stroke — all drugs for Ischemic Stroke →
- Atrial Fibrillation — all drugs for Atrial Fibrillation →
- Hemorrhagic Transformation Stroke — all drugs for Hemorrhagic Transformation Stroke →
Sponsor
University of Alberta
Who can join
18 and older, any sex, with Ischemic Stroke or Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Study Design: Lixiana Acute Stroke Evaluation Registry (LASER) is a randomized controlled trial with an associated registry. Patients with previously known or newly diagnosed atrial fibrillation (AF) and acute ischemic stroke within five days will be randomized 2:1 to early (≤ 5 days) or delayed (6-14 days) edoxaban initiation. Ischemic stroke will be defined as evidence of acute focal cerebral infarction confirmed on CT/MRI and/or focal hypoperfusion/vessel occlusion on multimodal CT, or by sudden focal and objective neurological deficits (i.e NIHSS ≥ 1) of presumed ischemic origin persisting \> 24 hours. Study Aim and Objectives: The primary aim of LASER is to demonstrate the safety of edoxaban initiation within five days of cardioembolic stroke. Secondary aim is to determine predictors of hemorrhagic transformation (HT) after cardioembolic stroke. Investigators will systematically assess prospectively collected Computed Tomography (CT) scan images for evidence of HT and re-infarction.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Update of Anticoagulation Use in Cardioembolic Stroke With a Special Reference to Endovascular Treatment.
Safouris A, Psychogios K, Palaiodimou L, Orosz P, et al · · 2024 · cited 5× · PMID 38326704 · DOI 10.5853/jos.2023.01578 -
Protocol for LASER: A Randomized Evaluation and an Associated Registry of Early Anticoagulation With Edoxaban After Ischemic Stroke in Patients With Atrial Fibrillation.
Alrohimi A, Jickling G, Jeerakathil T, Shuaib A, et al · · 2021 · cited 4× · PMID 33868150 · DOI 10.3389/fneur.2021.645822
Verify or expand the search:
- PubMed search for NCT03494530
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Edoxaban 60 MG
Trials testing the same drug.
- NCT04477837 — Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants · completed
- NCT03666650 — NOAC Plasma Concentration and Blood Coagulation in Healthy Volunteers · Phase 4 · completed
- NCT03083704 — A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa · Phase 1 · completed
Other recruiting trials for Ischemic Stroke
Currently open trials in the same condition.
- NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
- NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
- NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
- NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
- NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting
Other University of Alberta trials
Trials by the same sponsor.
- NCT03240900 — Electrical Stimulation for Improving Postoperative Breast Sensation · NA · not yet recruiting
- NCT04231760 — The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD · Phase 1, PHASE2 · not yet recruiting
- NCT06649604 — Reducing Pain From Retinal Laser With Vibrational Stimulation · NA · not yet recruiting
- NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle · EARLY_PHASE1 · not yet recruiting
- NCT06920914 — Effects of Minimally vs. Ultra-Processed Diets on Potassium (K) Handling in CKD · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03494530 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alberta
- Last refreshed: 5 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03494530.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing